Loading...

Media is loading
 

Date of Award

Spring 2024

Degree Name

Master of Medical Science (Physician Assistant)

Department

Physician Assistant; College of Health Sciences

First Advisor

Kaitlyn Gamber

Second Advisor

Alexa Arhontakis

Abstract

Diffuse Large B-cell Lymphoma is a malignant disorder of lymphocytes that appears with diffuse infiltration of lymphoid cells into lymph nodes or surrounding tissue such as the GI tract or central nervous system.1 It is the most common form of non-Hodgkin Lymphoma. Patients who are more likely to develop this lymphoma are individuals of ages 60 or older.2 .The standard first-line treatment involves combo chemotherapeutic regimen called R-CHOP. R-CHOP includes the following agents: rituximab, cyclophosphamide, doxorubicin HCl, vincristine and prednisone.

Additional Files

Lymphoma Presentation - final.pptx (1078 kB)

Share

COinS
 

Risk stratification, Treatment and Side Effect Management in Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma is a malignant disorder of lymphocytes that appears with diffuse infiltration of lymphoid cells into lymph nodes or surrounding tissue such as the GI tract or central nervous system.1 It is the most common form of non-Hodgkin Lymphoma. Patients who are more likely to develop this lymphoma are individuals of ages 60 or older.2 .The standard first-line treatment involves combo chemotherapeutic regimen called R-CHOP. R-CHOP includes the following agents: rituximab, cyclophosphamide, doxorubicin HCl, vincristine and prednisone.